Skye BioscienceFRA:09R -15.91%12 Market Cap is €21.62 Mil as of Jul. 03, 2026. GuruFocus rates FRA:09R with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,426 Biotechnology companies, Skye Bioscience ranks worse than 73.7% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Skye Bioscience's share price for the quarter that ended in Mar. 2026 was €0.466. Skye Bioscience's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 35.13 Mil. Therefore, Skye Bioscience's market cap for the quarter that ended in Mar. 2026 was €16.37 Mil.
Skye Bioscience's quarterly market cap
declined
from Sep. 2025 (€96.07 Mil) to Dec. 2025 (€20.36 Mil) and
declined
from Dec. 2025 (€20.36 Mil) to Mar. 2026 (€16.37 Mil).
Skye Bioscience's annual market cap
stayed the same
from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then
increased
from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€20.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Skye Bioscience's Enterprise Value for Today is €6.87 Mil.
Skye Bioscience (FRA:09R) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Skye Bioscience Market Cap Related Terms
Skye Bioscience Market Cap Historical Data
* Premium members only.
The historical data trend for Skye Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:09R vs PLRZ, NEUP, LGVN: Market Cap Comparison
For the Biotechnology subindustry, Skye Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skye Bioscience Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Skye Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Skye Bioscience's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Skye Bioscience's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skye Bioscience (FRA:09R) has a Market Cap of €21.62 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Skye Bioscience and its competitors. According to the industry distribution chart, Skye Bioscience ranks #1051 out of 1426 companies in the Biotechnology industry, placing it in the top 73.7%.
Is Skye Bioscience's Market Cap too high?
Skye Bioscience's current Market Cap is €21.62 Mil. Based on the distribution chart, Skye Bioscience ranks #1051 out of 1426 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Skye Bioscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Market Cap compare to PLRZ and NEUP?
According to the Biotechnology industry distribution chart, Skye Bioscience ranks #1051 out of 1426 companies for Market Cap. This places Skye Bioscience in the lower half of its industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Skye Bioscience and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skye Bioscience's current Market Cap is €21.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Market Cap of €21.62 Mil. The current Market Cap is €21.62 Mil. Skye Bioscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Market Cap is €21.62 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
12GF Score
Get the complete analysis for FRA:09R
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:09R has been successfully added to your 
